Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The possible usefulness of a medium cut-off dialyzer in a patient with cardiomyopathy of unclear origin
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Proteome of Hemodialysis Membranes: A Discovery Proteomic Pilot Study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Rationale for Expanded Hemodialysis Therapy (HDx)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The real-life study on expanded hemodialysis (HDx): 9 months experience of a single hemodialysis unit
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Rise of Expanded Hemodialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Theranova versus FX80: The impact on anemia management in hemodialysis.
Visit resource site
PD
Trends in outcomes for an automated peritoneal dialysis program with and without remote management in Colombia - Sanabria M et al.
Visit resource site
PD
Trends in outcomes for an automated peritoneal dialysis program with and without remote management in Columbia - Sanabria M, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
UK Clinical Experiences of a New Expanded Hemodialysis Therapy with a Novel Medium Cut-Off Dialyzer
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.